{"denoms":[{"counts":[{"groupId":"BG000","value":"143"},{"groupId":"BG001","value":"146"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"29"},{"groupId":"BG004","value":"341"}],"units":"Participants"}],"groups":[{"description":"Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.","id":"BG000","title":"Rituximab Retreatment: Follicular Patients"},{"description":"Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.","id":"BG001","title":"Rituximab Scheduled: Follicular Patients"},{"description":"Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.","id":"BG002","title":"Rituximab Retreatment: Non-Follicular Patients"},{"description":"Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.","id":"BG003","title":"Rituximab Scheduled: Non-Follicular Patients"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"25","upperLimit":"86","value":"59"},{"groupId":"BG001","lowerLimit":"25","upperLimit":"86","value":"58"},{"groupId":"BG002","lowerLimit":"47","upperLimit":"86","value":"61"},{"groupId":"BG003","lowerLimit":"38","upperLimit":"85","value":"65"},{"groupId":"BG004","lowerLimit":"25","upperLimit":"86","value":"60"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"186"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"155"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"As the primary analysis only includes randomized patients, the baseline characteristics were provided among patients who were correctly randomized to one of the two arms for maintenance therapy."}